In response to a comprehensive safety review prompted by a recent European study, the Medicines and Healthcare Products Regulatory Agency (MHRA) is introducing enhanced safety protocols for topiramate, commonly known by its brand name Topamax.
The Commission on Human Medicines (CHM) scrutinised research findings related to topiramate use during pregnancy. These studies revealed that children born to mothers who took topiramate faced a risk level approximately 2 to 3 times higher for intellectual disability, autism spectrum disorders, and attention deficit hyperactivity disorder.
